Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm, multicenter, phase III study to investigate the efficacy and safety of rituximab in Japanese patients with chronic immune thrombocytopenia.

Trial Profile

A single-arm, multicenter, phase III study to investigate the efficacy and safety of rituximab in Japanese patients with chronic immune thrombocytopenia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use

Most Recent Events

  • 13 May 2014 New trial record
  • 10 Dec 2013 The primary endpoint of "platelet count" has been met according to results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top